Navigation Links
Aeterna Zentaris Presents Positive Phase 2 Efficacy and Safety Data for AEZS-108 in Advanced Endometrial Cancer at ENA Meeting in Berlin, Germany
Date:11/18/2010

oncology using a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin. The product is in Phase 2 studies for the treatment of endometrial and ovarian cancer, and is also being studied for the treatment of other cancers. AEZS-108 is the first intravenous drug in a clinical study that directs the chemotherapy agent specifically to LHRH-receptor expressing tumors, resulting in more targeted treatment with less damage to healthy tissue. AEZS-108 has been granted orphan-drug designation by the FDA and orphan medicinal product designation from the EMA for the treatment of ovarian cancer. Aeterna Zentaris owns the worldwide rights to AEZS-108. About Aeterna Zentaris Inc. Aeterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, ovarian and endometrial cancer as well as multiple myeloma. The Company's innovative approach of "personalized medicine" means tailoring treatments to a patient's specific condition and to unmet medical needs. Aeterna Zentaris' deep pipeline is drawn from its proprietary discovery unit providing constant and long-term access to state-of-the-art therapeutic options. For more information please visit www.aezsinc.com. Forward-Looking Statements This press release contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties
'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany
2. Aeterna Zentaris Reports Third Quarter 2010 Financial and Operating Results
3. Aeterna Zentaris Announces Orphan Drug AEZS-130 (Macimorelin, Solorel(TM)) Interim Phase 3 Data Analysis Shows Potential for 2011 Filing as Oral Diagnostic Test for Adult Growth Hormone Deficiency (AGHD)
4. Aeterna Zentaris Announces NIH Grant for a Phase 1/2 Study in Advanced Prostate Cancer with AEZS-108
5. Aeterna Zentaris to Announce Second Quarter 2010 Financial and Operating Results on August 12, 2010
6. Aeterna Zentaris to Present at Upcoming Canaccord Genuity 30th Annual Growth Conference 2010 on August 12
7. Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma
8. Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer
9. Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer
10. Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering
11. Aeterna Zentaris to Raise US$12 Million in Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... integrated urological and interventional radiology products and services, ... known as cryotherapy and cryoablation) versus external beam ... Section of the American Urological Association (MAAUA) Annual ... , "Comparing Relative Effectiveness of Cryosurgery and External ...
(Date:9/18/2014)... -- Health Enhancement Products, Inc. (OTCQB: HEPI), a Michigan ... metabolic processes, is pleased to announce the addition of a ... Nola E. Masterson , a California -based ... 17, 2014. "We,re very pleased and honored ... Andrew Dahl , President and CEO. "She joins us ...
(Date:9/18/2014)... 2014 Research and Markets has ... Stem Cell Industry Report, 2014-2017" report to their ... cells that can differentiate into specialized cells and can ... cell therapy can be applied to treatment of cardiovascular ... system diseases, damage or lesion of liver, kidney and ...
(Date:9/18/2014)... 2014 Leatherwood Plastics has selected ... to stay competitive in the semiconductor, clean room ... ultimately impact product quality and productivity, according to ... Established in 1980 in Lewisville, TX, Leatherwood ... have left the business. Much of Leatherwood’s equipment ...
Breaking Biology Technology:HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2
... 23 Eisai Corporation of,North America and its ... Food and Drug Administration (FDA) has approved a ... prevention of,chemotherapy-induced nausea and vomiting (CINV). ALOXI Capsules ... prevention of acute nausea and,vomiting following initial and ...
... WuXi PharmaTech (NYSE:,WX), a leading pharmaceutical, biotechnology and ... in China and the United,States, today announced that ... of Synthetic Chemistry., (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ... Dr. Shuhui Chen, Chief Scientific,Officer of WuXi PharmaTech., ...
... Aug. 22 /PRNewswire-FirstCall/ - OncoGenex,Pharmaceuticals (NASDAQ: OGXI ... sodium, received Fast Track designation from the U.S. ... for progressive,metastatic prostate cancer. OGX-011 is currently completing ... breast cancer, and is designed to,inhibit the production ...
Cached Biology Technology:FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting 2FDA Approves ALOXI(R) (Palonosetron HCl) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting 3WuXi PharmaTech Promotes Dr. Rujian Ma to VP of Synthetic Chemistry 2FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 2FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 3FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011 4
(Date:9/18/2014)... A sleep-promoting circuit located deep in the primitive ... Discovered by researchers at Harvard School of Medicine and ... Sciences, this is only the second "sleep node" identified ... both necessary and sufficient to produce deep sleep. , ... the study demonstrates that fully half of all of ...
(Date:9/18/2014)... into the Crimean-Congo hemorrhagic fever virus (CCHFV), a tick-borne ... similar to that caused by Ebolavirus, has identified new ... the potential to lead to novel targets for therapeutic ... reported in a paper published today in the journal ... the Texas Biomedical Research Institute and their colleagues, represents ...
(Date:9/18/2014)... of researchers from McGill University and the Quebec ... polyethylene ,microbeads, Canadian Journal of Fisheries and ... from cosmetics, household cleansers, or industrial cleansers, to ... to their small size and buoyancy, they may ... are a global contaminant in the world,s oceans, ...
Breaking Biology News(10 mins):No sedative necessary: Scientists discover new 'sleep node' in the brain 2Research milestone in CCHF virus could help identify new treatments 2Microplastic pollution discovered in St. Lawrence River sediments 2
... press release is available in French . ... are not slower but rather wiser than young brains, which ... according research undertaken at the University Geriatrics Institute of Montreal ... Univeristy of Montreal. "The older brain has experience and knows ...
... important processes during drilling operations. In deepwater drilling, controlling pressure ... the drilled hole can result in blowouts, leading to disastrous ... The deeper the well, the higher the pressure, and the ... drilling, when the pressure applied to balance the hydrocarbon pressure ...
... scientists and collaborators has identified a cellular protein that plays ... online today in separate studies in the journal Nature, ... world,s most deadly viruses. Ebola causes hemorrhagic fever ... humans. The virus is of concern both as a global ...
Cached Biology News:Clinical study shows young brains lack the wisdom of their elders 2A math-based model for deep-water oil drilling 2A math-based model for deep-water oil drilling 3Single protein, key to ebola virus infection, could aid in drug design 2
... Kit #4 detects apoptosis on the ... permeability of cell membranes. This kit contains ... iodide nucleic acid stains. YO-PRO-1 stain selectively ... cells and labels them with moderate green ...
Request Info...
5-bromo-4-chloro-3-indolyl b -D-galactopyranoside (X-Gal)...
1+ mg expected yield of purified protein, expressed in insect cells - excludes cDNA...
Biology Products: